Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug stop prediabetes in its tracks?

NCT ID NCT07392151

Disease control Sponsor: Michael Mæng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether glucose-lowering medications (semaglutide and possibly dapagliflozin) can reverse prediabetes and prevent complications like eye, kidney, and nerve damage in people with heart disease. About 158 participants with prediabetes and coronary artery disease will be randomly assigned to either intensive treatment or standard care, and followed for two years. A third group of 50 people with normal blood sugar will serve as a comparison.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semaglutide and possibly Dapagliflozin
What this could lead to
If successful, this could show that treating prediabetes with these drugs can restore normal blood sugar and reduce the risk of diabetes-related complications.
What could go wrong
This is a relatively small trial (158 participants) and the drugs are not yet approved for prediabetes. Results may not apply to everyone, and side effects from the medications are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 158 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic coronary syndrome with documented coronary artery disease. In the case of previous myocardial infarction, at least 30 days between the event and randomization is required. * Prediabetes defined as HbA1c 42-47 mmol/mol (IEC criteria) OR normoglycemia defined as HbA1c \<39 mmol/mol * Age 18 to 80 years Exclusion Criteria: * eGFR \<30 mL/min/1.73 m2 * Previous diabetes diagnosis, previous HbA1c \>47 mmol/mol, or current/previous usage of diabetes medication * Anemia, recent bleeding or blood transfusion (\<3 months) * Previous pancreatitis * Pregnancy, breastfeeding, or fertile women who do not use highly effective contraception * Strongly reduced liver function * Chronic alcohol abuse * Known hemoglobinopathy and other conditions with effect on erythrocyte lifespan * Intake of medications with known effect on HbA1c validity such as: antiretroviral medications, trimethoprim, sulfamethoxazole, sulfasalazine hydroxyurea, dapsone, acetylsalicylic acid (\>3 g/daily), high dose vitamin C and E. * Heart failure with NYHA class III or IV Trial subjects must be capable of giving informed consent as assessed by the investigator. Patients with BMI\<25 kg/m2 will be assessed individually by an investigator for eligibility (e.g., whether initiation of a GLP-1 RA with potential weight loss is clinically justifiable).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder kidney disorder prediabetes syndrome retinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic coronary syndrome Prediabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus N, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.